JP2013536807A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536807A5
JP2013536807A5 JP2013526337A JP2013526337A JP2013536807A5 JP 2013536807 A5 JP2013536807 A5 JP 2013536807A5 JP 2013526337 A JP2013526337 A JP 2013526337A JP 2013526337 A JP2013526337 A JP 2013526337A JP 2013536807 A5 JP2013536807 A5 JP 2013536807A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
tumor
compound according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526337A
Other languages
English (en)
Japanese (ja)
Other versions
JP6039559B2 (ja
JP2013536807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/003949 external-priority patent/WO2012028243A1/en
Publication of JP2013536807A publication Critical patent/JP2013536807A/ja
Publication of JP2013536807A5 publication Critical patent/JP2013536807A5/ja
Application granted granted Critical
Publication of JP6039559B2 publication Critical patent/JP6039559B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526337A 2010-09-02 2011-08-05 Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体 Expired - Fee Related JP6039559B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009117 2010-09-02
EP10009117.2 2010-09-02
PCT/EP2011/003949 WO2012028243A1 (en) 2010-09-02 2011-08-05 Pyrazolopyridinone derivatives as lpa receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013536807A JP2013536807A (ja) 2013-09-26
JP2013536807A5 true JP2013536807A5 (cg-RX-API-DMAC7.html) 2014-09-18
JP6039559B2 JP6039559B2 (ja) 2016-12-07

Family

ID=44532738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526337A Expired - Fee Related JP6039559B2 (ja) 2010-09-02 2011-08-05 Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体

Country Status (10)

Country Link
US (2) US8859775B2 (cg-RX-API-DMAC7.html)
EP (1) EP2611808B1 (cg-RX-API-DMAC7.html)
JP (1) JP6039559B2 (cg-RX-API-DMAC7.html)
CN (1) CN103189378B (cg-RX-API-DMAC7.html)
AR (1) AR082880A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011297961B2 (cg-RX-API-DMAC7.html)
CA (1) CA2809892C (cg-RX-API-DMAC7.html)
ES (1) ES2530345T3 (cg-RX-API-DMAC7.html)
IL (1) IL225015A (cg-RX-API-DMAC7.html)
WO (1) WO2012028243A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9346757B2 (en) 2012-05-18 2016-05-24 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
RU2645344C2 (ru) * 2012-05-18 2018-02-21 Санофи Производные пиразола и их применение в качестве lpar5 антагонистов
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
IN2014MN02512A (cg-RX-API-DMAC7.html) * 2012-06-14 2015-07-17 Daiichi Sankyo Co Ltd
ES2753163T3 (es) * 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
WO2015050148A1 (ja) * 2013-10-04 2015-04-09 第一三共株式会社 ３－アリールピラゾロピリジン誘導体
WO2015076353A1 (ja) * 2013-11-25 2015-05-28 第一三共株式会社 ３－アルキルピラゾロピリジン誘導体
CA2923523A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
WO2015087995A1 (ja) * 2013-12-13 2015-06-18 第一三共株式会社 シクロアルキル又はヘテロシクリルピラゾロピリジン誘導体
BR112016013500B8 (pt) 2013-12-13 2020-07-14 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto
WO2015087996A1 (ja) * 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
EP3089986B1 (en) 2013-12-30 2019-06-26 Rxbio Inc. Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
WO2015111545A1 (ja) * 2014-01-21 2015-07-30 第一三共株式会社 縮合ピラゾール誘導体
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
TWI713534B (zh) * 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
RU2742608C2 (ru) * 2016-04-14 2021-02-09 Марс, Инкорпорейтед Способы идентификации модуляторов gpr92
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
US20210024520A1 (en) 2018-03-30 2021-01-28 Daiichi Sankyo Company, Limited Therapeutic agent for lcat deficiency
CN108558876B (zh) * 2018-05-28 2020-08-04 中南大学 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用
CN108379275B (zh) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 溶血磷脂酸、溶血磷脂酸受体3以及溶血磷脂酸受体3激动剂的应用
EP3846640A1 (en) 2018-09-07 2021-07-14 Mars Incorporated Compounds that modulate gpr92 receptor activity and pet food products containing the same
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
MX2021016133A (es) * 2019-06-20 2022-07-19 Univ Kentucky Res Found Moduladores de la neddilación de cullina mediada por dcn1/2 de tipo pirazolo piridona farmacéuticamente activos.
JP2023505704A (ja) 2019-12-12 2023-02-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｌｐａ受容体２阻害剤としてのキナゾリン誘導体
WO2021116259A1 (en) 2019-12-12 2021-06-17 Chiesi Farmaceutici S.P.A. Aromatic amido derivatives as lpa receptor 2 inhibitors
CA3157595A1 (en) * 2019-12-12 2021-06-17 Gabriele Amari Thienopyrimidine derivatives as lpa receptor 2 inhibitors
ES2991765T3 (es) 2020-07-16 2024-12-04 Chiesi Farm Spa Derivados del ácido amido ciclohexano como inhibidores del receptor de LPA
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022199815A1 (en) 2021-03-24 2022-09-29 Chiesi Farmaceutici S.P.A. 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
WO2023118253A1 (en) 2021-12-23 2023-06-29 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
US20250188068A1 (en) 2022-03-08 2025-06-12 Chiesi Farmaceutici S.P.A. Amido cyclopropyl derivatives as lpa receptor inhibitors
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US20040167192A1 (en) 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CA2525245C (en) * 2003-06-27 2010-10-19 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
US7217704B2 (en) 2003-10-09 2007-05-15 The University Of Tennessee Research Foundation LPA receptor agonists and antagonists and methods of use
EP1750722A4 (en) 2004-05-06 2010-03-10 Univ Virginia NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
WO2007139946A2 (en) * 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
SG10201609105YA (en) 2008-05-05 2016-12-29 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors

Similar Documents

Publication Publication Date Title
JP2013536807A5 (cg-RX-API-DMAC7.html)
AR082880A1 (es) Derivados de pirazolopiridinona como antagonistas del receptor de lpa
JP5826961B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類
CN102985421B (zh) 作为pi3k抑制剂用于治疗癌症和免疫-炎性疾病的萘啶衍生物
CN102209719B (zh) 新型前列腺素i2衍生物
JP2019519503A5 (cg-RX-API-DMAC7.html)
JP2020508302A5 (cg-RX-API-DMAC7.html)
JPWO2021081212A5 (cg-RX-API-DMAC7.html)
JP2013502404A (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
JP2010522152A5 (cg-RX-API-DMAC7.html)
JP2014534200A5 (cg-RX-API-DMAC7.html)
RU2017142005A (ru) 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора
JP2020534300A5 (cg-RX-API-DMAC7.html)
JP2007533635A5 (cg-RX-API-DMAC7.html)
JP2007529426A5 (cg-RX-API-DMAC7.html)
JP2019094260A (ja) 癌疾患治療用ナノ粒子化製剤
CN102917703B (zh) 新型ep4激动剂
JP2019522681A5 (cg-RX-API-DMAC7.html)
TWI694986B (zh) 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途
CN106084237B (zh) 一种聚磷酸酯-聚乳酸两嵌段共聚物及其制备方法和载药胶束
CN115867542A (zh) 新型苯并咪唑化合物
JP2004521126A5 (cg-RX-API-DMAC7.html)
CN107001617B (zh) Peg衍生物
JPWO2020204173A5 (cg-RX-API-DMAC7.html)
TW202340142A (zh) Ｇｃｌ抑制劑